Dexborneol
Large Vessel Occlusion
Beijing Tiantan HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Large Vessel Occlusion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tenecteplase Xuanwu Hospital, Beijing | Phase 3 | BB |
Semaglutide Wei Hu | Phase 3 | B |
Tirofiban Xuanwu Hospital, Beijing | Phase 3 | B |
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Beijing Tiantan Hospital | Phase 2 | CCC |
NORMAL HUMAN SERUM ALBUMIN Tianjin Huanhu Hospital | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Dexborneol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →